SEC Form 4 · accession 0002023732-26-000008
REGENXBIO Inc. · RGNX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gregory Austin Ciongoli
Director
Period of report
Aug 25, 2026
Accepted (ET)
Aug 27, 2026 · 7:03 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001590877
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 25, 2026 | A | 15,432 | $0.00 | A | 15,432 | D | |
| Common StockF2 | Aug 26, 2026 | P | 49,196 | $9.1411 | A | 64,628 | D | |
| Common StockF3 | Aug 27, 2026 | P | 53,407 | $9.356 | A | 118,035 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (Right to buy)F4 | $8.91 | Aug 25, 2026 | A | 69,609 | A | Aug 25, 2027 | Aug 25, 2036 | Common Stock | 69,609 | 69,609 | D |
Explanation of responses
- F1Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 1/3rd of the shares subject to the RSU award shall vest on each of August 25, 2027, August 25, 2028 and August 25, 2029, while the recipient provides continuous service to the Issuer.
- F2Represents shares purchased in an open-market transaction. The price reported in Column 4 is a weighted average price. This transaction was executed in multiple trades at prices ranging from $8.67 to $9.35. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3Represents shares purchased in an open-market transaction. The price reported in Column 4 is a weighted average price. This transaction was executed in multiple trades at prices ranging from $9.17 to $9.4525. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4The option will vest over a three year period, with 1/3rd of the option vesting on August 25, 2027 and the remaining portion of the option vesting in equal monthly installments over the 24 months thereafter, while the optionee provides continuous service to the Issuer.